ARS Pharmaceuticals Inc
SPRY9.720USD
-0.080-0.82%
終値 09/29, 16:00（ET）15分遅れの株価
959.34M時価総額
損失額直近12ヶ月PER
詳細情報 ARS Pharmaceuticals Inc 企業名
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
ARS Pharmaceuticals Incの企業情報
企業コードSPRY
会社名ARS Pharmaceuticals Inc
上場日Dec 04, 2020
最高経営責任者「CEO」Mr. Richard E. Lowenthal
従業員数155
証券種類Ordinary Share
決算期末Dec 04
本社所在地11682 El Camino Real, Suite 120
都市SAN DIEGO
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号92130
電話番号18587719307
ウェブサイトhttps://ars-pharma.com/
企業コードSPRY
上場日Dec 04, 2020
最高経営責任者「CEO」Mr. Richard E. Lowenthal
ARS Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Justin Chakma
Mr. Justin Chakma
Chief Business Officer
Chief Business Officer
136.38K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Rajeev Dadoo, Ph.D.
Dr. Rajeev Dadoo, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Justin Chakma
Mr. Justin Chakma
Chief Business Officer
Chief Business Officer
136.38K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Wed, Sep 3
更新時刻: Wed, Sep 3
株主統計
種類
株主統計
株主統計
比率
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.70%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
他の
61.13%
株主統計
株主統計
比率
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.70%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
他の
61.13%
種類
株主統計
比率
Hedge Fund
21.29%
Investment Advisor
19.30%
Investment Advisor/Hedge Fund
18.57%
Venture Capital
15.07%
Individual Investor
12.08%
Private Equity
8.39%
Corporation
4.88%
Research Firm
2.70%
Sovereign Wealth Fund
0.44%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
367
96.00M
97.76%
-11.66M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
2023Q2
278
88.26M
96.94%
-730.20K
2023Q1
271
88.79M
98.08%
+1.91M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
RA Capital Management, LP
10.86M
11.06%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
8.29M
8.44%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
10.51M
10.71%
--
--
Mar 31, 2025
Lowenthal (Richard E)
6.83M
6.95%
-1.14M
-14.34%
Mar 31, 2025
Pratik Shah Living Trust
4.82M
4.91%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.66%
-556.66K
-10.85%
Mar 31, 2025
SR One Capital Management, LP
4.01M
4.09%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.88M
3.95%
-275.85K
-6.63%
Mar 31, 2025
AllianceBernstein L.P.
3.92M
3.99%
+42.07K
+1.08%
Mar 31, 2025
The Vanguard Group, Inc.
3.48M
3.54%
+23.34K
+0.68%
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
